[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
作者信息
Bergmann L
出版信息
Strahlenther Onkol. 2001 May;177(5):273-4.
PMID:11398617
Abstract
摘要
相似文献
1
[Aromatase inhibitors: anastrozole versus tamoxifen as first-ine therapy for advanced postmenopausal breast cancer].
Strahlenther Onkol. 2001 May;177(5):273-4.
2
Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.
Am J Clin Oncol. 2003 Jun;26(3):317-22. doi: 10.1097/01.COC.0000047126.10522.F9.
3
Focus on anastrozole and breast cancer.
Curr Med Res Opin. 2003;19(8):683-8. doi: 10.1185/030079903125002397.
4
New treatment option for postmenopausal women with early breast cancer.
Expert Rev Anticancer Ther. 2002 Dec;2(6):617. doi: 10.1586/14737140.2.6.617.
5
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
J Clin Oncol. 2001 May 1;19(9):2578; author reply 2580-2.
6
Anastrozole as an adjuvant endocrine treatment for postmenopausal patients with breast cancer: emerging data.
Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):1037s-1048s. doi: 10.1158/1078-0432.CCR-05-2458.
7
Adjuvant endocrine therapy in postmenopausal breast cancer.
Clin Cancer Res. 2003 Jan;9(1 Pt 2):480S-5S.
8
Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
Clin Ther. 2004 Sep;26(9):1546-61. doi: 10.1016/j.clinthera.2004.09.014.
9
Cost utility analysis of first-line hormonal therapy in advanced breast cancer: comparison of two aromatase inhibitors to tamoxifen.
Am J Clin Oncol. 2003 Jun;26(3):289-96. doi: 10.1097/01.COC.0000021042.55557.2B.
10
Role of new selective aromatase inhibitor in therapy for metastatic breast cancer in postmenopausal women.
Nurse Pract. 1997 Mar;22(3):195-6, 201-2.
Zotero 插件